Rutherford, NJ – May 18, 2011 – Cancer Genetics, Inc. (CGI), a life science company focused on personalized cancer medicine, today announced it has appointed Elizabeth A. Czerepak as Chief Financial Officer. In this role, Ms. Czerepak will lead the finance, clinical billing operations, human resources, and administrative support functions. She will report directly to Panna Sharma, President and CEO, and will be an officer of the Company.

“We’re fortunate to have Elizabeth join the management team at a time when CGI is growing through technology advancement, collaborations and partnerships,” said Panna Sharma, CEO of CGI. “Elizabeth’s experience in biotech finance, venture capital, business development and licensing will be instrumental as we pursue several avenues to commercialize molecular diagnostics products and laboratory services, and to evolve CGI into a leading personalized cancer treatment company. We’re pleased to welcome Elizabeth to the CGI team.”

Ms. Czerepak, 55, brings 28 years of industry experience to CGI. She is a founder of BIOptima Advisors, a consulting firm providing business development, strategic planning and clinical advisory services to biotechnology and pharmaceutical companies. Most recently, Ms. Czerepak was Managing Director at Bear, Stearns & Co.,later JP Morgan, where she founded Bear Stearns Health Innoventures (BSHI), a $212 million venture capital fund that led investments in thirteen biotechnology companies. From 1982 to 2000, Ms. Czerepak held senior positions in licensing, business development and finance at BASF Pharma, Hoffmann-La Roche and Merck & Co.

Ms. Czerepak earned an MBA from Rutgers University and graduated magna cum laude with a B.A. in Secondary Education from Marshall University. She is a member of Licensing Executives Society and serves on the Board of Directors of ToleRx, Inc.

# # #

About CGI
Based in of Rutherford, NJ, CGI was founded by Dr. R.S.K. Chaganti in 1999 and has become an emerging leader in personalized cancer treatment. CGI’s synergistic business model provides cancer-focused diagnostic testing services to leading oncologists, pathologists, hospitals, and academic centers as well as the development of next-generation diagnostic products that leverage CGI’s unique IP in molecular genetics and oncology. Products developed by CGI are revolutionizing the management and treatment of certain cancers while reducing healthcare costs. Information about the company can be found on the Internet at: www.cancergenetics.com.

Contact:
Panna Sharma
(201) 528-9191
psharma@cancergenetics.com

Learn more at http://www.the-scientist.com/bptw/

- Partnership to help biotechnology and pharmaceutical companies bring next generation oncology therapeutics to market in a more targeted and effective manner -

Rutherford, NJ – March 23, 2011 – Cancer Genetics, Inc. (CGI) and Aptiv Solutions have formed a strategic partnership focused on delivering comprehensive solutions to biopharmaceutical and medical device firms conducting clinical trials for oncology therapeutics. CGI provides disease-specific biomarker knowledge, proprietary molecular testing and oncology lab services to sponsor companies during the early stages of clinical trials. Aptiv Solutions provides a portfolio of innovative services including adaptive trial design, early phase product strategy, regulatory services, pharmacovigilance, and the operational support of a global clinical research organization.

Together, CGI and Aptiv Solutions will provide biopharmaceutical firms with a better understanding of modes of action of a variety of therapeutics and the role for biomarkers in the oncology drug development process. Early insight in complex diseases and complicated patients garnered by using genomic technologies and other methodologies will drive informed decisions and successful development of targeted therapies, personalized medicine and other new therapeutics. The collaboration will provide customers with the products and services necessary to bring oncology therapeutics to their patients faster and at a reduced cost.

“Integrated clinical information is critical to providing customized patient treatment in which drug usage and dosage can be specifically targeted to the individual patient’s genetic requirement,” said Panna Sharma, Chief Executive Officer of CGI. “As a leader in personalized medicine, CGI is confident that this collaboration will assist our clients in the development of new therapeutics and diagnostics by reducing the time frame and costs for regulatory approval through patient stratification.”

“We are excited about partnering with CGI to enhance our ability to offer molecular and genetic laboratory expertise to our clients,” said Gene Resnick, MD, Chief Medical Officer for Aptiv Solutions. “We recognize the critical role of biomarkers in the development of new agents in oncology and other therapeutic areas, and look forward to bringing a combined solution to the pharmaceutical, biotech and medical device industries which will enable clients to accelerate the progress of more efficient clinical trials. Adding this capacity to our existing expertise in oncology trial management will bring a value-add for sponsors and ultimately for patients.”

# # #

About CGI

Based in of Rutherford, NJ, CGI was founded by Dr. R.S.K. Chaganti in 1999 and has become an emerging leader in personalized cancer treatment. CGI’s synergistic business model provides cancer-focused diagnostic testing services to leading oncologists, pathologists, hospitals, and academic centers as well as the development of next-generation diagnostic products that leverage CGI’s unique IP in molecular genetics and oncology. Products developed by CGI are revolutionizing the management and treatment of certain cancers while reducing healthcare costs. Information about the company can be found on the Internet at: www.cancergenetics.com.

About Aptiv Solutions

Aptiv Solutions is a global biopharmaceutical and medical device development services organization, focused on recognizing, understanding and enabling clients to capitalize on rapid and fundamental changes they face in developing products in the pharmaceutical, biotech and medical device market. Aptiv Solutions integrates the resources and expertise of six recently merged companies: Averion International, Trio Clinical Research, Fulcrum Pharma, ClinResearch, Niphix and ADDPLAN.

The Aptiv Solutions legacy companies, Averion International, Trio Clinical Research, ClinResearch, and Niphix have conducted hundreds of oncology trials in both the drug and device areas at thousands of clinical sites with hundreds of thousands of patients. Aptiv Solutions provides innovative, comprehensive and proven product development capabilities, built on an extensive portfolio of services and a worldwide team of more than 700 professionals. Additional information: www.aptivsolutions.com.

Contact:

Panna Sharma

(201) 528-9191

psharma@cancergenetics.com

Rutherford, NJ – www.cancergenetics.com – Cancer Genetics, Inc (CGI), an emerging leader in personalized treatment for cancer, has been awarded 3 grants to further commercialize molecular diagnostics for oncology. CGI has announced that these grants were issued from the Qualifying Therapeutic Discovery Project program under section 48D of the Internal Revenue Code. This program was created under the Affordable Care Act and is aimed to fund projects and initiatives that demonstrate the ability to advance new therapies, reduce long-term healthcare costs, or take steps to curing cancer within the next 30 years. CGI’s founder, Dr. R.S.K. Chaganti says, “The success with this award is a clear validation of CGI’s novel approaches and innovative technologies towards taking molecular diagnostics of cancer to the next level.” The three funded projects cover personalized treatment and diagnosis in the areas of: mature B-cell neoplasms, HPV-associated cancers, and renal cancer. CGI is expected to commercialize these products over the next year, with an initial launch in late November of 2010 of the first application of the mature B-cell neoplasm microarray, MatBA™.

The Qualifying Therapeutic Discovery Project program was allotted $1 billion for credits and grants to fund projects designed to improve health and save lives. The IRS, in conjunction with the Department of Health and Human Services, reviewed applications for projects that showed significant potential to produce new and cost-saving therapies, support jobs and increase U.S. competitiveness. Projects aimed in the determination of molecular factors through the use of molecular diagnostics to guide therapeutic decisions were highly regarded in the selection process. CGI aims to develop diagnostic assays for prognosis of cancer that help to guide effective treatments and reduce healthcare costs. The funding is geared towards making testing and diagnostic services more affordable, allow for further clinical trials, and educate medical personnel on the information and usage of CGI products.

Qualified Therapeutic Discovery Projects at CGI:

MatBA™
A microarray-based comparative genomic hybridization (CGH) assay developed to detect chromosomal gains and losses frequently observed in mature B-cell neoplasms. In it’s first version MatBA™-CLL, DNA gains and losses in chronic lymphocytic leukemia (CLL) over and above that currently reported by fluorescence in-situ hybridization (FISH), are detected and physicians can utilize the results to assist in the diagnosis and prognosis of CLL.

FHACT™
Used as a patented-pending diagnostic tool, FHACT™ is a FISH-based assay that can identify chromosomal changes in HPV-associated cancers. FHACT™, when used as a reflex test for abnormal cytology specimens, will provide an additional level of triage to patients and assist clinicians in determining the most suitable treatment for the patient that is the least invasive and most cost-effective.

FReCaD™
This FISH-based renal cancer detection (FReCaD™) assay is designed to differentially diagnose the four main subtypes of renal cortical neoplasms, three of which are malignant and one benign. By detecting genomic copy number alterations inherent to the renal cancer subtypes, the FReCaD™ assay allows a more accurate diagnosis of image-guided pre-operative fine needle aspirates and biopsies subsequently guiding  personalized clinical management of an ever increasing aging population in which suspect renal masses are detected..

About Cancer Genetics, Inc (CGI)

Based in of Rutherford, NJ, CGI was founded by Dr. R.S.K. Chaganti in 1999 and has become an emerging leader in personalized cancer treatment. CGI’s synergistic business model provides cancer-focused diagnostic testing services to leading oncologists, pathologists, hospitals, and academics centers as well as the development of next-generation diagnostic products that leverage CGI’s unique IP in molecular genetics and oncology. Products developed by CGI are revolutionizing the management and treatment of certain cancers as well as reducing healthcare costs. The company can be found on the Internet at www.cancergenetics.com or reached at (201) 528-9200.

Contact: Marie-Agnès Patrone-Michellod
mmichellod@cancergenetics.com
(201) 528-9182

The grant was awarded for the next year and amounts to slightly above $275,000 USD. Based on the progress we make, we will be able to apply for an additional $369,000 USD in mid-2011.

This grant continues to reinforce CGI as the leader in combining leading edge cytogenetic and molecular research in cancer with real clinical needs and utility. Kidney cancer causes approximately 13,000 deaths in the US each year and an estimated 58,200 new cases were uncovered in 2008/09. There is a real need for earlier and more differentiated diagnosis, especially with the limited amounts of tissue aspirate that is usually available from clinical cases. This project will result in the development of fundamental IP for CGI in the areas of FISH based detection, molecular cytogenetics and decision-tree development for kidney cancer treatment.

U.S. Patent #7,585,964 (assigned September 2009)

CGI was awarded this patent in September 2009. Chromosomal Translocation is a significant chromosomal abnormality and CGI is pleased to to be a part of providing the necessary research and development to enable early detection of cancer through cytogenetics.

This invention describes probes and methods of using probes to detect chromosomal rearrangements to provide greater selectivity and sensitivity. The probe sets utilized in the detection methods are designed to hybridize to chromosomes at regions outside known breakpoints, instead of spanning the breakpoint as with conventional FISH methods, and, in some instances, are further designed to bind to regions located outside the genes involved in the rearrangement. Probe sets for four translocations have been designed by CGI:

(11;14)(q13; q32) (BCL1; IGH)

t(14;18)(q32; q21) (IGH; BCL2)

t(8;14)(q24; q32) (MYC; IGH)

t(9;22)(q34; q11) (BCR; ABL)